As the tumor microenvironment (TME) suppresses CD8+ T cell trafficking and function due to multiple effects, oncolytic virotherapy offers the potential to overcome this by eliciting an adaptive immune response both against the viral infection and the tumor [33]. This evidence concerns the gene CD8A and neoplasm.